a:5:{s:8:"template";s:9184:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="text/html; charset=utf-8" http-equiv="content-type"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Roboto+Condensed%3A300%2C300i%2C400%2C400i%2C600%2C600i%2C800%2C800i&amp;subset=latin%2Clatin-ext" id="bulk-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}p.has-drop-cap:not(:focus)::first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}p.has-drop-cap:not(:focus)::after{content:"";display:table;clear:both;padding-top:14px} @font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:300;src:local('Roboto Condensed Light Italic'),local('RobotoCondensed-LightItalic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVg2ZhZI2eCN5jzbjEETS9weq8-19eDpCEoY9Nc.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:400;src:local('Roboto Condensed Italic'),local('RobotoCondensed-Italic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVj2ZhZI2eCN5jzbjEETS9weq8-19eLAQM4.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:300;src:local('Roboto Condensed Light'),local('RobotoCondensed-Light'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVi2ZhZI2eCN5jzbjEETS9weq8-33mZGCoYag.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:400;src:local('Roboto Condensed'),local('RobotoCondensed-Regular'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVl2ZhZI2eCN5jzbjEETS9weq8-19y7CA.ttf) format('truetype')} /*! normalize.css v3.0.3 | MIT License | github.com/necolas/normalize.css */html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}.text-center{text-align:center}ul{margin-top:0;margin-bottom:10px}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-brand{float:left;padding:15px 15px;font-size:18px;line-height:20px;height:50px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}@media (min-width:768px){.navbar-right{float:right!important;margin-right:-15px}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{content:" ";display:table}.container-fluid:after,.container:after,.nav:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}body,html{overflow-x:hidden}body{font-family:'Roboto Condensed',"Helvetica Neue",helvetica,arial,sans-serif;padding:0;color:#404040;font-weight:400;line-height:1.8;font-size:16px;word-wrap:break-word;overflow-x:hidden}a,a:active,a:focus,a:hover{text-decoration:none;color:#0090ff}ul{padding-left:20px}a:active{border-bottom:none}.page-area{padding-top:70px}@media (min-width:768px){.navbar-nav>li>a{padding-top:25px;padding-bottom:25px;transition:all .5s ease-in-out;-moz-transition:all .5s ease-in-out;-webkit-transition:all .5s ease-in-out;-o-transition:all .5s ease-in-out}#site-navigation .container{padding-left:0;padding-right:0}}@media (max-width:767px){.navbar-nav a:focus,.navbar-nav a:hover{color:#fff!important;background-color:#000!important}.menu-container{width:70%;position:absolute;left:0;height:100vh;transform:translate3d(-100%,0,0);overflow-y:auto;overflow-x:auto;background-color:#fff;top:100%}.navbar-brand{padding-right:55px!important}.page-area{left:0;transform:translate3d(0,0,0);transition:transform .5s ease}.navbar-nav{padding:0;margin:0}.navbar-nav a{font-size:14px;padding:12px 10px!important;margin:0!important;line-height:16px!important;float:left!important;margin:0!important;width:100%;text-transform:none!important;word-wrap:break-word;white-space:normal!important}.navbar-nav li{padding:0!important;margin:0!important}}#site-navigation{min-height:70px}.navbar-nav>li>a{border-bottom:0;text-transform:uppercase}.site-title{margin:0;padding:0;font-size:22px;line-height:28px}p.site-description{font-size:13px;line-height:18px;margin:0;-webkit-transition:all .5s ease;transition:all .5s ease}.site-branding-logo{float:left}.site-branding-logo a{border:none;z-index:9999;position:relative}.navbar-brand{padding:10px 15px;height:auto;z-index:99999;position:relative;z-index:1}.navbar{margin-bottom:0}.main-menu{position:relative}.navbar-fixed-top{position:absolute}#site-navigation{background-color:#fff;-webkit-box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);border:none}#site-navigation,nav a{-webkit-transition:all .3s ease;transition:all .3s ease;color:#000}.footer-credits{border-top:1px solid #ccc;padding:15px;clear:both;margin-top:20px;background-color:#fff}</style>
 </head>
<body class="wp-custom-logo" id="blog">
<div class="main-menu">
<nav class="navbar navbar-default navbar-fixed-top" id="site-navigation">
<div class="container">
<div class="navbar-header">
<div class="site-header">
<div class="site-branding-logo">
<a class="custom-logo-link" href="#" itemprop="url" rel="home"></a> </div>
<div class="site-branding-text navbar-brand">
<p class="site-title"><a href="#" rel="home">{{ keyword }}</a></p>
<p class="site-description">
{{ keyword }}</p>
</div>
</div>
</div>
<div class="menu-container"><ul class="nav navbar-nav navbar-right" id="menu-menu-1"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-72 dropdown" id="menu-item-72"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="Projects">Projects</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73 dropdown" id="menu-item-73"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="About">About</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-74" id="menu-item-74"><a href="#" title="Contacts">Contacts</a></li>
</ul></div> </div>
</nav>
</div>
<div class="page-area">	
{{ text }}
<br>
<br>
{{ links }}
</div>
<footer class="footer-credits container-fluid row" id="colophon">
<div class="container">
<p class="footer-credits-text text-center">{{ keyword }} 2020</p>
</div>
</footer>
</body>
</html>";s:4:"text";s:7198:"Flatiron expanded into the Southeast two decades ago and quickly became a local builder and partner of choice. Considering that this network is highly specialized and focused on oncology, the acquisition provides Roche even greater competitive advantage in the oncology drugs market. The closing of the transaction is subject to customary closing conditions. This important milestone will allow us to increase our investments in our provider-facing technology and services platform, as well as our evidence-generation platform, which will remain available to the entire healthcare industry.”. Nat Turner, Flatiron Health Co-Founder and CEO said, “Roche has been a tremendous partner to us over the past two years and shares our vision for building a learning healthcare platform in oncology ultimately designed to improve the lives of cancer patients. Flatiron may help Roche expedite market launch and save R&D cost for its upcoming oncology drugs. Another interesting aspect is that Roche also has a stake in Foundation Medicine, which is a genomics analysis company. We are curious to see whether Flatiron integration and acquisition will have a similar fate. Roche has agreed to acquire Flatiron Health for $1.9 billion in cash. Across the U.S. and Canada, we build highways, bridges, airports, rail transit, dams, water facilities and… Although Future Outcomes Seem Promising, Operational and Integration Factors will be Important for Future Success. Email piyush.bansal@frost.com and speak to a thought leader in this field. The Company provides oncologists and hospitals with a more comprehensive view of their patient population, and what cancers they are facing. If you would like more insights on the Roche’s acquisition, please connect with us! Genentech, in the United States, is a wholly owned member of the Roche Group. The transaction is expected to close in the first half of 2018. Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US, is a market leader in oncology-specific electronic health record (EHR) software, as well as the curation and development of real-world evidence for cancer research. In 2018, health-tech start-ups raised more than $8 billion, but the only significant exits came from a few acquisitions, like Roche's purchase of Flatiron Health for … A free inside look at Flatiron Health salary trends based on 145 salaries wages for 62 jobs at Flatiron Health. Prior to … By using our website you agree to our use of cookies in accordance with our cookie policy. There are enough regulatory barriers that prohibit a pharmaceutical company from directly collaborating with a provider in the US. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Flatiron is the trusted provider of innovative solutions to infrastructure challenges. As far as the current situation for Flatiron goes, everything looks promising except a few minor issues. The Flatiron platform enables cancer researchers and care providers to learn from the experience of every patient. A key principle of this is to preserve Flatiron’s autonomy and their ability to continue providing their services to all existing and future partners.”. EquityZen’s proprietary technology enables lower minimums for investors and sellers. It also captures unstructured data from sources such as laboratories, research repositories, payer networks, among others, and its analytics engine pulls out relevant insights from the unstructured data, which, when combined with electronic medical records (EMR) data, generate the real-world evidence. Oncology therapeutics contributes ~60% of the total revenue of Roche, and it is critical to maintaining the market leadership to sustain business performance. Swiss drug giant Roche is set to buy cancer data specialist Flatiron Health for $1.9 billion. All Rights Reserved, This is a BETA experience. This market direction is likely to push other pharmaceutical manufacturers to look for next-gen technology adoption to remain competitive in the market. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Oncology therapeutic companies have started 2018 on a high note. Drug giant Roche (OTCQX:RHHBY) has announced an agreement to acquire Flatiron Health for $1.9 billion. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. This article is exclusive for subscribers. But one thing is clear—Roche’s decision was not driven by Flatiron’s healthcare provider-client lists. This article was written with contributions from Piyush Bansal, Life Sciences Senior Industry Analyst in Frost & Sullivan’s Transformational Health Practice. Incentives for Roche – Stride towards Gaining Leadership in Highly Competitive Oncology Therapeutics Market.  With the patent of its key drugs Rituxan, Herceptin, and Avastin set to expire in 2018, 2019 and 2020, respectively, only in the U.S., it is essential for the company to fast-track the development and approval of new drugs. With over 25 years of…. However, it is expected that Roche might focus on developing specific tools/platforms utilizing Flatiron’s expertise for its exclusive usage. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. Flatiron Health has worked with industry leaders and regulators to develop new approaches for how real-world evidence may be used in regulatory decision making, including the design and validation of novel endpoints. Experts are criticizing Flatiron for not providing incentives to clinical trial enrollees or to patients who had agreed to submit their genomic insight in OncoEMR. The Flatiron platform is able to help identify the right patient cohorts for almost 15 types of cancer conditions for clinical trials, which can help save developers millions of dollars. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. With its large network of community oncology practices and academic medical centers across the US, Flatiron Health has created a technology platform designed to learn from the experience of every patient. A free inside look at company reviews and salaries posted anonymously by employees. All trademarks used or mentioned in this release are protected by law. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. You may opt-out by. Some thought processes suggest that Roche could have intervened early to safeguard its own interest. In such a critical business situation, the company is in dire need of utilizing real-world evidence and analytics solutions to fast track its clinical trials. ";s:7:"keyword";s:21:"flatiron health stock";s:5:"links";s:1266:"<a href="http://newdestinychurchpc.com/blog/article.php?tag=walter-payton-man-of-the-year-2020-6bb478">Walter Payton Man Of The Year 2020</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=punk%27d-quibi-6bb478">Punk'd Quibi</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=mitch-green-2020-6bb478">Mitch Green 2020</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=examples-of-non-deferrable-expenses-6bb478">Examples Of Non-deferrable Expenses</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=johnson-and-johnson-glassdoor-interview-6bb478">Johnson And Johnson Glassdoor Interview</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=vito-scotti-columbo-episodes-6bb478">Vito Scotti Columbo Episodes</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=pattie-boyd-6bb478">Pattie Boyd</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=bermane-stiverne-net-worth-6bb478">Bermane Stiverne Net Worth</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=urology-products-manufacturers-6bb478">Urology Products Manufacturers</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=pfizer-stock-forecast-2025-6bb478">Pfizer Stock Forecast 2025</a>,
";s:7:"expired";i:-1;}